tiprankstipranks
BeOne Medicines (MX:ONCN)
NASDAQ:ONCN
Mexico Market
ONCN
BeOne Medicines
RESEARCH TOOLSreports

BeOne Medicines (ONCN) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

ONCN Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
BeOne
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ONCN Stock 12 Month Forecast

Average Price Target

$7,083.09
Based on 13 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $7,083.09 with a high forecast of $7,920.41 and a low forecast of $5,944.68. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2529":"$2,529","3877":"$3,877","5225":"$5,225","6573":"$6,573","7921":"$7,921"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7920.41123403,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7083.0856402161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5944.6795134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.94K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2529,3877,5225,6573,7921],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2530,2944.6470180023075,3359.2940360046155,3773.941054006923,4188.588072009231,4603.235090011538,5017.882108013846,5432.529126016154,5847.176144018462,6261.823162020769,6676.470180023077,7091.117198025385,7505.764216027692,{"y":7920.41123403,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2530,2880.2373569397,3230.4747138794,3580.7120708190996,3930.9494277588,4281.1867846985,4631.424141638199,4981.6614985779,5331.8988555176,5682.1362124573,6032.373569396999,6382.6109263367,6732.848283276399,{"y":7083.0856402161,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2530,2792.6676548769233,3055.335309753846,3318.0029646307694,3580.670619507692,3843.3382743846155,4106.005929261539,4368.673584138462,4631.341239015384,4894.008893892308,5156.676548769231,5419.344203646155,5682.0118585230775,{"y":5944.6795134,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2530,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2530,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7,920Average Price Target$7,083Lowest Price Target$5,945
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on MX:ONCN
Sean Laaman
Morgan Stanley
Morgan Stanley
$6,906.32
Buy
―
Reiterated
07/23/26
Morgan Stanley Reaffirms Their Buy Rating on BeOne Medicines (ONC)
J.P. Morgan Analyst forecast on MX:ONCN
Jessica Fye
J.P. Morgan
J.P. Morgan
$7,256.01→$7,430.85
Buy
―
Reiterated
07/23/26
BeOne Medicines price target raised to $425 from $415 at JPMorganBeOne Medicines price target raised to $425 from $415 at JPMorgan
Barclays Analyst forecast on MX:ONCN
Etzer Darout
Barclays
Barclays
$7,151.1→$7,046.19
Buy
―
Reiterated
07/14/26
BeOne Medicines (ONC) Gets a Buy from Barclays
Jefferies Analyst forecast on MX:ONCN
Faisal Khurshid
Jefferies
Jefferies
$5,822.29→$6,644.05
Buy
―
Upgraded
07/12/26
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
RBC Capital Analyst forecast on MX:ONCN
Leonid Timashev
RBC Capital
RBC Capital
$7,623.18→$7,885.44
Buy
―
Reiterated
07/07/26
BeOne Medicines price target raised to $451 from $436 at RBC CapitalBeOne Medicines price target raised to $451 from $436 at RBC Capital
Truist Financial Analyst forecast on MX:ONCN
Gregory Renza
Truist Financial
Truist Financial
$7,221.04→$7,273.49
Buy
―
Reiterated
07/07/26
BeOne Medicines price target raised to $416 from $413 at TruistBeOne Medicines price target raised to $416 from $413 at Truist
Wolfe Research Analyst forecast on MX:ONCN
Kalpit Patel
Wolfe Research
Wolfe Research
$5,944.68
Buy
―
Reiterated
07/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on MX:ONCN
Michael Schmidt
Guggenheim
Guggenheim
$7,343.43
Buy
―
Reiterated
06/15/26
Guggenheim Remains a Buy on BeOne Medicines (ONC)
Citi Analyst forecast on MX:ONCN
Yigal Nochomovitz
Citi
Citi
$7,920.41
Buy
―
Reiterated
06/12/26
BeOne Medicines (ONC) Gets a Buy from Citi
TD Cowen Analyst forecast on MX:ONCN
Yaron Werber
TD Cowen
TD Cowen
$7,413.37
Buy
―
Reiterated
06/02/26
TD Cowen Remains a Buy on BeOne Medicines (ONC)
Leerink Partners Analyst forecast on MX:ONCN
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$6,364.3→$6,416.76
Buy
―
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
CMB International Securities Analyst forecast on MX:ONCN
Jill Wu
CMB International Securities
CMB International Securities
$6,861.38
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)
Wells Fargo Analyst forecast on MX:ONCN
Yanan Zhu
Wells Fargo
Wells Fargo
$6,993.74
Buy
―
Reiterated
05/07/26
BeOne Medicines (ONC) Gets a Buy from Wells Fargo
Bernstein Analyst forecast on MX:ONCN
Rebecca Liang
Bernstein
Bernstein
$7,203.55
Buy
―
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on MX:ONCN
David Li
Bank of America Securities
Bank of America Securities
$6,801.41→$7,032.21
Buy
―
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on MX:ONCN
Sean Laaman
Morgan Stanley
Morgan Stanley
$6,906.32
Buy
―
Reiterated
07/23/26
Morgan Stanley Reaffirms Their Buy Rating on BeOne Medicines (ONC)
J.P. Morgan Analyst forecast on MX:ONCN
Jessica Fye
J.P. Morgan
J.P. Morgan
$7,256.01→$7,430.85
Buy
―
Reiterated
07/23/26
BeOne Medicines price target raised to $425 from $415 at JPMorganBeOne Medicines price target raised to $425 from $415 at JPMorgan
Barclays Analyst forecast on MX:ONCN
Etzer Darout
Barclays
Barclays
$7,151.1→$7,046.19
Buy
―
Reiterated
07/14/26
BeOne Medicines (ONC) Gets a Buy from Barclays
Jefferies Analyst forecast on MX:ONCN
Faisal Khurshid
Jefferies
Jefferies
$5,822.29→$6,644.05
Buy
―
Upgraded
07/12/26
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
RBC Capital Analyst forecast on MX:ONCN
Leonid Timashev
RBC Capital
RBC Capital
$7,623.18→$7,885.44
Buy
―
Reiterated
07/07/26
BeOne Medicines price target raised to $451 from $436 at RBC CapitalBeOne Medicines price target raised to $451 from $436 at RBC Capital
Truist Financial Analyst forecast on MX:ONCN
Gregory Renza
Truist Financial
Truist Financial
$7,221.04→$7,273.49
Buy
―
Reiterated
07/07/26
BeOne Medicines price target raised to $416 from $413 at TruistBeOne Medicines price target raised to $416 from $413 at Truist
Wolfe Research Analyst forecast on MX:ONCN
Kalpit Patel
Wolfe Research
Wolfe Research
$5,944.68
Buy
―
Reiterated
07/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on MX:ONCN
Michael Schmidt
Guggenheim
Guggenheim
$7,343.43
Buy
―
Reiterated
06/15/26
Guggenheim Remains a Buy on BeOne Medicines (ONC)
Citi Analyst forecast on MX:ONCN
Yigal Nochomovitz
Citi
Citi
$7,920.41
Buy
―
Reiterated
06/12/26
BeOne Medicines (ONC) Gets a Buy from Citi
TD Cowen Analyst forecast on MX:ONCN
Yaron Werber
TD Cowen
TD Cowen
$7,413.37
Buy
―
Reiterated
06/02/26
TD Cowen Remains a Buy on BeOne Medicines (ONC)
Leerink Partners Analyst forecast on MX:ONCN
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$6,364.3→$6,416.76
Buy
―
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
CMB International Securities Analyst forecast on MX:ONCN
Jill Wu
CMB International Securities
CMB International Securities
$6,861.38
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)
Wells Fargo Analyst forecast on MX:ONCN
Yanan Zhu
Wells Fargo
Wells Fargo
$6,993.74
Buy
―
Reiterated
05/07/26
BeOne Medicines (ONC) Gets a Buy from Wells Fargo
Bernstein Analyst forecast on MX:ONCN
Rebecca Liang
Bernstein
Bernstein
$7,203.55
Buy
―
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on MX:ONCN
David Li
Bank of America Securities
Bank of America Securities
$6,801.41→$7,032.21
Buy
―
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
KURAKura Oncology
GKOSGlaukos
AHCOAdaptHealth
VTVTvTv Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months
Jill WuCMB International Securities
Success Rate
11/18 ratings generated profit
61%
Average Return
+4.02%
Copying Jill Wu's trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +4.02% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
31/35 ratings generated profit
89%
Average Return
+37.30%
Copying Yaron Werber's trades and holding each position for 1 Year would result in 88.57% of your transactions generating a profit, with an average return of +37.30% per trade.
2 Years
Jill WuCMB International Securities
Success Rate
16/18 ratings generated profit
89%
Average Return
+42.96%
Copying Jill Wu's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +42.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONCN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
6
6
Buy
20
19
24
22
25
Hold
1
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
20
26
29
32
In the current month, ONCN has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ONCN average Analyst price target in the past 3 months is 7,083.09.
Each month's total comprises the sum of three months' worth of ratings.

ONCN Financial Forecast

ONCN Earnings Forecast

Next quarter’s earnings estimate for ONCN is $28.54 with a range of $10.68 to $61.98. The previous quarter’s EPS was $34.32. ONCN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ONCN has Performed in-line its overall industry.
Next quarter’s earnings estimate for ONCN is $28.54 with a range of $10.68 to $61.98. The previous quarter’s EPS was $34.32. ONCN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ONCN has Performed in-line its overall industry.

ONCN Sales Forecast

Next quarter’s sales forecast for ONCN is $28.34B with a range of $26.95B to $30.33B. The previous quarter’s sales results were $26.58B. ONCN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ONCN has Performed in-line its overall industry.
Next quarter’s sales forecast for ONCN is $28.34B with a range of $26.95B to $30.33B. The previous quarter’s sales results were $26.58B. ONCN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year ONCN has Performed in-line its overall industry.

ONCN Stock Forecast FAQ

What is MX:ONCN’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines’s 12-month average price target is 7,083.09.
    What is MX:ONCN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:ONCN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BeOne Medicines a Buy, Sell or Hold?
        BeOne Medicines has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
          What is BeOne Medicines’s share price target?
          The average share price target for BeOne Medicines is 7,083.09. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $7,920.41 ,and the lowest forecast is $5,944.68. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about BeOne Medicines?
            BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of BeOne Medicines?
              To buy shares of MX:ONCN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.